Skip to main content
TISSUE REGENIX GROUP PLC logo

TISSUE REGENIX GROUP PLC — Investor Relations & Filings

Ticker · TRX ISIN · GB00BNTXR104 LEI · 213800PNOD5UHQUFJI36 IL Manufacturing
Open in API
Filings indexed 405 across all filing types
Latest filing 2025-01-15 Major Shareholding Noti…
Country GB United Kingdom
Listing IL TRX

About TISSUE REGENIX GROUP PLC

https://www.tissueregenix.com/

Tissue Regenix Group PLC is a medical technology company specializing in regenerative medicine. The company develops and commercializes biological products designed to repair and regenerate human tissue. It employs proprietary decellularization platform technologies to process human and animal tissues, creating acellular scaffolds. When implanted, these scaffolds support the patient's own cells in repopulating and regenerating the damaged area. The company's portfolio serves three main clinical areas: biosurgery for complex wound care, orthopaedics for sports medicine and bone graft substitutes, and dental applications for tissue and bone repair. Key products include DermaPure®, OrthoPure® XT, and the Matrix® line of bone graft substitutes.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains structured data regarding the acquisition or disposal of voting rights by a shareholder (Lexham Special Opportunities I LP), detailing the resulting percentage of voting rights (5.798709%). This format is characteristic of regulatory filings related to significant ownership changes. The presence of 'RNS Number' and the closing statement referencing the London Stock Exchange and the Financial Conduct Authority confirms it is a regulatory disclosure. This specific type of disclosure, reporting changes in major shareholdings, maps directly to the Major Shareholding Notification category.
2025-01-15 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains fields related to the 'acquisition or disposal of voting rights' and 'Total positions of person(s) subject to the notification obligation', showing percentage changes in share ownership (e.g., moving from 12.22% to 13.01%). This structure is characteristic of regulatory filings reporting changes in significant shareholdings. The RNS Number and the mention of the FCA confirm it is a regulatory disclosure. This directly matches the definition for Major Shareholding Notification (MRQ).
2025-01-13 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is clearly identified as an 'RNS Number' filing from 'Tissue Regenix Group PLC' dated '09 December 2024'. The content is structured as a 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, which directly corresponds to the definition of Major Shareholding Notification. Therefore, the appropriate code is MRQ.
2024-12-09 English
Extended distribution agreement with Arthrex, Inc.
Regulatory Filings Classification · 1% confidence The document starts with an 'RNS Number' and contains information typical of a regulatory news service announcement from the London Stock Exchange (LSE). The content announces a business event: the extension of a distribution agreement between Tissue Regenix's subsidiary and Arthrex, Inc. This is a material corporate event announcement that does not fit the specific categories like Earnings Release (ER), Annual Report (10-K), or Director's Dealing (DIRS). Since it is a general regulatory announcement provided via RNS and doesn't fit a more specific category (like M&A, Capital Change, or Dividend), the most appropriate classification is the general Regulatory Filings category, RNS.
2024-11-26 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly labeled as an 'RNS Number' notification from 'Tissue Regenix Group PLC' dated '20 November 2024'. The content is structured as a 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, which directly corresponds to the definition of a Major Shareholding Notification. Therefore, the appropriate code is MRQ.
2024-11-20 English
Form 8 (OPD) (Tissue Regenix Group Plc)
Major Shareholding Notification Classification · 1% confidence The document is explicitly titled 'FORM 8 (OPD) PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER' and references 'Rules 8.1 and 8.2 of the Takeover Code (the "Code")'. This form is used to disclose interests and short positions related to a takeover offer. This specific disclosure relates to director dealings and shareholdings in the context of an offer, which falls under insider/director transaction reporting related to corporate actions. While it contains director information (Section 3A), its primary purpose is mandated by the Takeover Code regarding an offer situation. The closest specific category is Director's Dealing (DIRS), as it details holdings by directors, but the context is a takeover disclosure (Form 8). Since there is no specific 'Takeover Disclosure' code, and it involves director/insider positions, DIRS is a strong candidate, but the overall structure strongly suggests a regulatory filing related to a specific event (the offer). Given the options, 'Director's Dealing' (DIRS) captures the nature of the disclosed information (director holdings/options) even though the form is a specific Takeover Code filing. However, since it is a formal, structured regulatory disclosure mandated by the Takeover Panel, and not just a routine director trade report, it is best classified as a general Regulatory Filing (RNS) or potentially a specific type of transaction report. Since the document is a formal disclosure required by the Takeover Code, and it details director holdings/options in the context of an offer, it is a specific regulatory filing. Given the options, and recognizing it is a formal disclosure required by a regulatory body (Takeover Panel), RNS (Regulatory Filings) is the most appropriate general category for structured, non-standard reports not covered elsewhere. It is not a standard 10-K, ER, or IR. It is a specific regulatory filing related to an offer.
2024-11-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.